Perceptive Advisors LLC Sells 2,055,997 Shares of Singular Genomics Systems, Inc. (NASDAQ:OMIC)

Perceptive Advisors LLC decreased its holdings in Singular Genomics Systems, Inc. (NASDAQ:OMIC) by 96.7% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 70,896 shares of the company’s stock after selling 2,055,997 shares during the quarter. Perceptive Advisors LLC owned about 2.87% of Singular Genomics Systems worth $599,000 as of its most recent filing with the Securities & Exchange Commission.

Analyst Upgrades and Downgrades

Separately, The Goldman Sachs Group reduced their target price on Singular Genomics Systems from $22.50 to $6.50 and set a “neutral” rating on the stock in a report on Tuesday, July 9th.

Singular Genomics Systems Stock Down 0.1 %

NASDAQ:OMIC opened at $15.49 on Monday. Singular Genomics Systems, Inc. has a 1-year low of $5.34 and a 1-year high of $19.80. The company has a market capitalization of $38.21 million, a PE ratio of -0.39 and a beta of 1.34. The firm’s 50-day moving average price is $8.87 and its 200-day moving average price is $10.63. The company has a debt-to-equity ratio of 0.05, a current ratio of 8.77 and a quick ratio of 8.04.

Singular Genomics Systems (NASDAQ:OMIC) last announced its earnings results on Tuesday, August 13th. The company reported ($8.57) earnings per share for the quarter, beating analysts’ consensus estimates of ($8.86) by $0.29. Singular Genomics Systems had a negative net margin of 3,375.72% and a negative return on equity of 54.66%. The business had revenue of $0.74 million during the quarter, compared to the consensus estimate of $0.40 million.

About Singular Genomics Systems

Singular Genomics Systems, Inc, a life science technology company, develops next generation sequencing and multiomics technology for researchers and clinicians to advance science and medicine. The company is involved in the developing of G4, consisting of G4 instrument and associated consumables for various applications, such as max read kits for single cell sequencing, rare variant detection with high-definition sequencing, gene fusion detection with ring-seq, and extended range sequencing; and PX instrument and associated consumables for applications comprising single cell gene expression and proteomics, in situ RNA sequencing, and spatial RNA and proteomics applications for tissue.